ArticleJournal of thoracic disease2025
Prognostic factors for non-small cell lung cancer after neoadjuvant therapy and surgery: a retrospective observational study.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advances in neoadjuvant immunotherapy for non-small cell lung cancer.Frontiers in immunology · 2026Review
- Combining immune checkpoint inhibitors with thoracic radiotherapy enhances outcomes in advanced non-small-cell lung cancer: a real-world study.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neoadjuvant therapy, given before surgery, improves surgical outcomes and survival in patients with non-small cell lung cancer (NSCLC). However, there is limited research on factors influencing postoperative survival and recurrence. This study aims to identify key prognostic factors following lung resection after neoadjuvant therapy. Methods: We analyzed 102 NSCLC cases with preoperative neoadjuvant therapy, excluding 48 due to cancer progression, insufficient clinical data, loss to follow up, or follow-up duration of <1 year. The Kaplan-Meier and multivariable Cox regression model were used to assess prognostic factors for the time from surgery to recurrence or last follow-up [recurrence-free survival (RFS)] and the time from surgery to death from any cause or last follow-up [overall survival (OS)]. Statistical comparisons were performed using Results: Univariate and multivariate analyses identified pre-neoadjuvant carcinoembryonic antigen (CEA) and neutrophil-to-lymphocyte ratio (NLR) as significant predictors of both RFS [pre-neoadjuvant CEA: hazard ratio (HR) =12.190, 95% confidence interval (CI): 2.236-66.459, P=0.004; pre-neoadjuvant NLR: HR =2.946, 95% CI: 1.325-6.552, P=0.008] and OS (pre-neoadjuvant CEA: HR =3.545, 95% CI: 1.372-9.161, P=0.009; pre-neoadjuvant NLR: HR =3.783, 95% CI: 1.444-9.909, P=0.007) in NSCLC. And these factors were especially predictive in groups of lung squamous cell carcinoma (LUSC) and <10% residual tumor. CEA and NLR were stronger predictors of RFS than OS, with HRs of 7.751 and 5.627, respectively. Smoking was an independent predictor of RFS in LUSC patients (P<0.05). A >50% reduction in tumor size on post-neoadjuvant computed tomography (CT) correlated with minimal pathological response (P<0.05). Age, pre-neoadjuvant CEA, NLR, programmed cell death protein 1 (PD-1) levels, and changes in mediastinal lymph nodes on post-neoadjuvant CT were significantly associated with tumor recurrence (P<0.05). Conclusions: Pre-neoadjuvant CEA and NLR are predictors of postoperative survival. Other factors, including tumor size reduction and PD-1 levels, should be considered in clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.